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Summary
Each year, the American Heart Association (AHA), in con-
junction with the Centers for Disease Control and Preven-
tion, the National Institutes of Health, and other government 
agencies, brings together the most up-to-date statistics related 
to heart disease, stroke, and other cardiovascular and met-
abolic diseases and presents them in its Heart Disease and 
Stroke Statistical Update . The Statistical Update represents 
a critical resource for the lay public, policy makers, media 
professionals, clinicians, healthcare administrators, research-
ers, and others seeking the best available data on these con-
ditions . Together, cardiovascular disease (CVD) and stroke 
produce immense health and economic burdens in the United 
States and globally . The Statistical Update brings together in 
a single document up-to-date information on the core health 
behaviors and health factors that define cardiovascular health; 
a range of major clinical disease conditions (including stroke, 
congenital heart disease, rhythm disorders, subclinical ath-
erosclerosis, coronary heart disease, heart failure, valvular 
disease, and peripheral arterial disease); and the associated 
outcomes (including quality of care, procedures, and eco-
nomic costs) . Since 2009, the annual versions of the Statisti-
cal Update have been cited >20 000 times in the literature . In 
2014 alone, the various Statistical Updates were cited >5700 
times .
Each annual version of the Statistical Update undergoes 
major revisions to include the newest nationally representa-
tive data, add additional relevant published scientific findings, 
remove older information, add new sections or chapters, and 
increase the number of ways to access and use the assembled 
information . This year-long process, which begins as soon as 
the previous Statistical Update is published, is performed by 
the AHA Statistics Committee faculty volunteers and staff . 
For example, this year’s edition includes a new chapter on 
cardiac arrest, new data on the monitoring and benefits of car-
diovascular health in the population, additional information 
in many chapters on the global CVD and stroke burden, and 
further new focus on evidence-based approaches to changing 
behaviors, implementation strategies, and implications of the 
AHA’s 2020 Impact Goals . Below are a few highlights from 
this year’s Update .
Current Status of Cardiovascular Health in the 
United States (Chapter 2)
●● The concept of cardiovascular health represents a height-
ened focus for the AHA, with 3 central and novel emphases:
—An expanded focus on not only CVD prevention but also 
promotion of positive cardiovascular health, in addition 
to the treatment of established CVD .
—The prioritization of both health behaviors (healthy 
diet pattern, appropriate energy intake, physical activ-
ity [PA], and nonsmoking) and health factors (optimal 
blood lipids, blood pressure, glucose levels) throughout 
the lifespan as primary goals unto themselves .
—Population-level health promotion strategies to shift 
the majority of the public toward greater cardiovascu-
lar health, in addition to targeting those individuals at 
greatest CVD risk, because CVD occurs at all risk levels 
across the population and because healthy lifestyles are 
uncommon throughout the US population .
●● The prevalence of ideal cardiovascular health is higher 
in US children and young adults than in US middle-aged 
and older adults, largely because of the higher prevalence 
of ideal levels of health factors in US children and young 
adults . However, with regard to health behaviors, children 
and young adults were similar to (PA) or worse than (diet) 
middle-aged and older adults . Poor diet and physical inac-
tivity in childhood and younger age are strong predictors of 
suboptimal health factors later in life .
●● Approximately 50% of US children 12 to 19 years of age 
have ≥5 metrics at ideal levels, with lower prevalence in 
girls (47%) than in boys (52%) .
●● Only 18% of US adults have ≥5 metrics with ideal levels, 
with lower prevalence in men (11%) than in women (25%) .
●● Among children, the prevalence of ideal levels of cardio-
vascular health behaviors and factors currently varies from 
<1% for the healthy diet pattern (ie, <1 in 100 US children 
meets at least 4 of the 5 dietary components) to >80% for 
the smoking, blood pressure, and fasting glucose metrics .
●● Among US adults, the prevalence of ideal levels of cardio-
vascular health behaviors and factors currently varies from 
0 .5% for the healthy diet pattern to up to 78% for the smok-
ing metric (never having smoked or being a former smoker 
who has quit for >12 months) .
Effective Approaches to Improve Cardiovascular 
Health (Chapter 2)
●● The current evidence supports a range of complementary 
strategies to improve cardiovascular health, including:
—Individual-focused approaches, which target lifestyle 
and treatments at the individual level
—Healthcare systems approaches, which encourage, facili-
tate, and reward efforts by providers to improve health 
behaviors and health factors
—Population approaches, which target lifestyle and treat-
ments in schools or workplaces, local communities, and 
states, as well as throughout the nation
●● Such approaches can focus on both (1) improving cardio-
vascular health among those who currently have less than 
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optimal levels and (2) preserving cardiovascular health 
among those who currently have ideal levels (in particu-
lar, children, adolescents, and young adults) as they age .
●● The metrics with the greatest potential for improvement 
are health behaviors, including diet quality, PA, and body 
weight . However, each of the cardiovascular health metrics 
can be improved and deserves major focus .
●● The AHA has a broad range of policy initiatives to improve 
cardiovascular health among all Americans and meet the 
2020 Strategic Impact Goals .
Health Behaviors (Chapters 3 to 6)
Based on comparable risk assessment methods, poor lifestyle 
behaviors and lifestyle-related risk factors are the foremost causes 
of death and disability in the United States and in the world .
Smoking/Tobacco Use (Chapter 3)
●● Although tobacco use has declined substantially in the 
United States, it remains the second-leading cause of total 
deaths and disability . The percentage of adults who reported 
current cigarette use declined from 24 .1% in 1998 to 17 .9% 
in 2013; among high school students, the decline was from 
36 .4% in 1997 to 15 .7% in 2013 . Still, almost one third of 
coronary heart disease deaths are attributable to smoking 
and exposure to secondhand smoke .
●● Declines in tobacco usage in the United States may be threat-
ened by the >250 e-cigarette products that were available in 
2014 . To date, the risks and benefits of e-tobacco products 
remain controversial but are an area of intense investigation 
by scientists, as well as scrutiny by the US Food and Drug 
Administration . Public health experts are concerned that 
e-cigarettes may be a gateway to smoking traditional ciga-
rettes and may be eroding gains in the public’s awareness of 
the harms of tobacco products .
●● Annual smoking-attributable economic costs in the United 
States, including direct medical costs and lost productivity, 
are estimated to exceed $289 billion .
Physical Inactivity (Chapter 4)
●● In 2013, 15 .2% of adolescents reported being inactive during 
the prior week, and inactivity was more likely to be reported 
by girls (19 .2%) than boys (11 .2%) . Inactivity was more 
commonly reported by black (27 .3%) and Hispanic (20 .3%) 
girls than their white counterparts (16 .1%); similarly, black 
(15 .2%) and Hispanic (12 .1%) boys reported more inactivity 
than white boys (9 .2%) .
●● According to 2013 National Health Interview Survey data, 
only half of American adults met the current aerobic PA 
guidelines (≥150 minutes of moderate PA or 75 minutes 
of vigorous PA or an equivalent combination each week) . 
Women (46 .1%) were less likely to meet the guidelines 
than men (54 .2%), and non-Hispanic blacks (41 .4%) and 
Hispanics (42 .9%), were less likely to meet them than non-
Hispanic whites (53 .4%) .
●● Unfortunately, the proportion of individuals meeting PA 
recommendations is likely to be lower than indicated by 
self-report data . Studies examining actual (with accelerom-
eters, pedometers, etc) versus self-reported PA indicate that 
both men and women overestimate their PA substantially 
(by 44% and 138% for men and women, respectively) .
Nutrition (Chapter 5)
●● The leading risk factor for death and disability in the 
United States is suboptimal diet quality, which in 2010 
led to 678 000 annual deaths of all causes . Major contribu-
tors were insufficient intakes of fruits, nuts/seeds, whole 
grains, vegetables, and seafood, as well as excess intakes 
of sodium . In the United States, an estimated 58 000 annual 
CVD deaths (95% confidence interval, 37 000–80 000) in 
2010 were attributable to sodium intake >2 .0 g/d, repre-
senting 1 in 16 (6 .3%) of all CVD deaths and 1 in 8 (13 .1%) 
CVD deaths before age 70 years . Globally, an estimated 
1 .65 million annual CVD deaths (95% confidence interval, 
1 .10–2 .22) were attributable to sodium intake >2 .0 g/d, rep-
resenting nearly 1 in 10 (9 .5%) of all CVD deaths .
●● Although healthier diets cost modestly more than unhealth-
ful diets, comparing extremes of unhealthful versus healthful 
food-based diet patterns, the more healthful patterns cost on 
average ≈$1 .50 per day more . Similarly priced options are 
also common; in a comparison of 20 fruits and vegetables ver-
sus 20 common snack foods such as cookies, chips, pastries, 
and crackers, the average price per portion of fruits and vege-
tables was 31 cents, with an average of 57 calories per portion, 
versus 33 cents and 183 calories per portion for snack foods .
Obesity (Chapter 6)
●● Although the overall prevalence of obesity in US youth did 
not change between 2003 to 2004 and 2011 to 2012, the 
prevalence decreased among those aged 2 to 5 years . Obe-
sity decreased among those of higher socioeconomic status 
but increased among those of lower socioeconomic status . In 
addition, the overall prevalence of severe obesity in US youth 
continued to increase, especially among adolescent boys .
●● Overweight and obesity predispose individuals to most 
major risk factors, including physical inactivity, hyperten-
sion, hyperlipidemia, and diabetes mellitus .
●● Excess body weight is among the leading causes of death 
and disability in the United States and globally, with bur-
dens expected to increase in coming years .
●● Among overweight and obese individuals, existing cardio-
metabolic risk factors should be monitored and treated inten-
sively with diet quality, PA, and pharmacological or other 
treatments as necessary . Each of these interventions pro-
vides benefits independent of weight loss and maintenance .
Health Factors and Other Risk Factors  
(Chapters 7 to 12)
The prevalence and control of cardiovascular health factors 
and risks remains a major issue for many Americans .
Family History and Genetics (Chapter 7)
●● Familial aggregation of CVD is related to the clustering of 
specific lifestyle factors and risk factors, both of which have 
environmental and genetic contributors . Patients with a fam-
ily history of coronary artery disease have a higher prevalence 
of traditional CVD risk factors, underscoring opportunities for 
prevention .
●● The risk of most CVD conditions is higher in the presence 
of a family history, including CVD (45% higher odds with 
sibling history), stroke (50% higher odds with history in 
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a first-degree relative), atrial fibrillation (AF, 80% higher 
odds with parental history), heart failure (70% higher odds 
with parental history), and peripheral arterial disease (80% 
higher odds with family history) .
High Blood Cholesterol and Other Lipids (Chapter 8)
●● 75 .7% of children and 46 .6% of adults have ideal choles-
terol levels (untreated total cholesterol <170 mg/dL for 
children and <200 mg/dL for adults) . Prevalence of ideal 
levels has improved over the past decade in children but 
remained the same in adults .
●● According to 2009 to 2012 data, >100 million US adults 
≥20 years of age have total cholesterol levels ≥200 mg/dL; 
almost 31 million have levels ≥240 mg/dL .
High Blood Pressure (Chapter 9)
●● Based on 2009 to 2012 data, 32 .6% of US adults ≥20 years 
of age have hypertension, which represents ≈80 .0 million 
US adults . African American adults have among the highest 
prevalence of hypertension in the world . Among non-His-
panic black men and women, the age-adjusted prevalence 
of hypertension was 44 .9% and 46 .1%, respectively .
●● National Health and Nutrition Examination Survey 
(NHANES) data from 2009 to 2012 revealed that among 
US adults with hypertension, 54 .1% were controlled, 
76 .5% were currently treated, 82 .7% were aware they had 
hypertension, and 17 .3% were undiagnosed .
Diabetes Mellitus (Chapter 10)
●● Diabetes mellitus affects 1 in 10 US adults, with 90% to 95% 
of cases being type 2 diabetes mellitus . Diabetes mellitus dis-
proportionately affects racial/ethnic minorities . Type 2 diabetes 
mellitus is increasingly common in children and adolescents; 
the disease historically was diagnosed primarily in adults ≥40 
years of age . The prevalence of type 2 diabetes mellitus in chil-
dren/adolescents has increased by 30 .5% between 2001 and 
2009, and it now constitutes ≈50% of all childhood diabetes 
mellitus .
●● Diabetes mellitus is associated with reduced longevity, with 
men with diabetes mellitus living an average of 7 .5 years 
and women with diabetes mellitus living an average of 8 .2 
years less than their counterparts without diabetes mellitus .
Metabolic Syndrome (Chapter 11)
●● From 1999 to 2010, the age-adjusted national prevalence 
of metabolic syndrome in the United States peaked (in 
the 2001–2002 cycle) and began to fall . This is attribut-
able to decreases in the age-adjusted prevalence among 
women and no change in men . In addition, there has been 
variation in the trends over time for each individual com-
ponent of the metabolic syndrome . Generally, the national 
prevalences of hypertriglyceridemia and elevated blood 
pressure have decreased, whereas hyperglycemia and ele-
vated waist circumference have increased . However, these 
trends also vary significantly by sex and race/ethnicity .
Cardiovascular Conditions/Diseases  
(Chapters 13 to 22)
Rates of death attributable to CVD have declined in the United 
States, but the burden remains high .
Total Cardiovascular Diseases (Chapter 13)
●● The 2011 overall rate of death attributable to CVD was 
229 .6 per 100 000 Americans . The death rates were 275 .7 
for males and 192 .3 for females . The rates were 271 .9 
for white males, 352 .4 for black males, 188 .1 for white 
females, and 248 .6 for black females .
●● From 2001 to 2011, death rates attributable to CVD declined 
30 .8% . In the same 10-year period, the actual number of 
CVD deaths per year declined by 15 .5% . Yet in 2011, CVD 
still accounted for 31 .3% (786 641) of all 2 515 458 deaths, 
or ≈1 of every 3 deaths in the United States .
●● On the basis of 2011 death rate data, >2150 Americans die 
of CVD each day, an average of 1 death every 40 seconds . 
Approximately 155 000 Americans who died of CVD in 
2011 were <65 years of age . In 2011, 34% of deaths attrib-
utable to CVD occurred before the age of 75 years, which 
is younger than the current average life expectancy of 78 .7 
years .
Stroke (Chapter 14)
●● From 2001 to 2011, the relative rate of stroke death fell by 
35 .1% and the actual number of stroke deaths declined by 
21 .2% . Yet each year, ≈795 000 people continue to experi-
ence a new or recurrent stroke (ischemic or hemorrhagic) . 
Approximately 610 000 of these are first events and 185 000 
are recurrent stroke events . In 2011, stroke caused ≈1 of 
every 20 deaths in the United States . On average, every 40 
seconds, someone in the United States has a stroke, and 
someone dies of one approximately every 4 minutes .
●● The decline in stroke mortality over the past decades, a 
major improvement in population health observed for both 
sexes and all race and age groups, has resulted from reduced 
stroke incidence and lower case fatality rates . The signifi-
cant improvements in stroke outcomes are concurrent with 
cardiovascular risk factor control interventions . The hyper-
tension control efforts initiated in the 1970s appear to have 
had the most substantial influence on the accelerated decline 
in stroke mortality, with lower blood pressure distributions 
in the population . Control of diabetes mellitus and high 
cholesterol and smoking cessation programs, particularly 
in combination with hypertension treatment, also appear to 
have contributed to the decline in stroke mortality .
Atrial Fibrillation (Chapter 16)
●● Multiple lines of evidence have increased awareness of the 
burden of unrecognized AF . In individuals without a history 
of AF with recent pacemaker or defibrillator implantation, 
subclinical atrial tachyarrhythmias were detected in 10 .1% 
of patients . Subclinical atrial tachyarrhythmias were associ-
ated with a 5 .6-fold higher risk of clinical AF and ≈13% of 
ischemic strokes or embolism . A recent systematic review 
suggested that one needs to screen 170 community-based 
individuals at least 65 years of age to detect 1 case of AF .
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Sudden Cardiac Arrest (Chapter 17)
●● In 2011, ≈326 200 people experienced emergency medi-
cal services–assessed out-of-hospital cardiac arrests in the 
United States . Survival to hospital discharge after nontrau-
matic EMS-treated cardiac arrest with any first recorded 
rhythm was 10 .6% for patients of any age . Of the 19 300 
bystander-witnessed out-of-hospital cardiac arrests in 
2011, 31 .4% of victims survived .
●● Each year, ≈209 000 people are treated for in-hospital cardiac 
arrest .
Coronary Heart Disease (Chapter 19)
●● Coronary heart disease alone caused ≈1 of every 7 deaths 
in the United States in 2011 . In 2011, 375 295 Americans 
died of coronary heart disease . Each year, an estimated 
≈635 000 Americans have a new coronary attack (defined 
as first hospitalized myocardial infarction or coronary heart 
disease death) and ≈300 000 have a recurrent attack . It is 
estimated that an additional 155 000 silent first myocardial 
infarctions occur each year . Approximately every 34 sec-
onds, 1 American has a coronary event, and approximately 
every 1 minute 24 seconds, an American will die of one .
Heart Failure (Chapter 20)
●● In 2011, 1 in 9 death certificates (284 388 deaths) in the 
United States mentioned heart failure . Heart failure was 
the underlying cause in 58 309 of those deaths . The num-
ber of any-mention deaths attributable to heart failure was 
approximately as high in 1995 (287 000) as it was in 2011 
(284 000) . Additionally, hospital discharges for heart fail-
ure remained stable from 2000 to 2010, with first-listed 
discharges of 1 008 000 and 1 023 000, respectively .
Cardiovascular Quality of Care, Procedure 
Utilization, and Costs (Chapters 23 to 25)
The Statistical Update provides critical data in several sec-
tions on the magnitude of healthcare delivery and costs, as 
well as the quality of healthcare delivery, related to CVD risk 
factors and conditions .
Quality-of-Care Metrics for CVD (Chapter 23)
●● The Institute of Medicine has identified 6 domains of qual-
ity of care, including safety, effectiveness, patient-centered 
care, timely care, efficiency, and equitable care .
●● According to the Medicare Patient Safety Monitoring System, 
between 2005 and 2011, adverse event rates in hospitalized 
patients declined for both myocardial infarction (from 5 .0% to 
3 .7%) and congestive heart failure (from 3 .7% to 2 .7%)
●● However, in the American College of Cardiology’s Practice 
Innovation and Clinical Excellence (PINNACLE) outpa-
tient registry, only 66 .5% of eligible patients with coronary 
artery disease received the optimal evidenced-based com-
bination of medications .
●● A randomized trial of post–acute coronary care syn-
drome that used multiple modalities to enhance adher-
ence to 4 indicated medications (clopidogrel, statins, 
angiotensin-converting enzyme inhibitors/angioten-
sin receptor blockers, and β-blockers) demonstrated 
better adherence in the intervention group (89 .3% versus 
73 .9%) at 1 year .
●● Similarly, challenges persist in the outpatient setting, in 
discussion and counseling for PA and dietary habits .
Cardiovascular Procedure Use and Costs  
(Chapters 24 and 25)
●● The total number of inpatient cardiovascular operations and 
procedures increased 28% between 2000 and 2010, from 
5 939 000 to 7 588 000 .
●● According to the 2012 National Healthcare Cost and Utili-
zation Project statistics, the mean hospital charge for a vas-
cular or cardiac surgery or procedure in 2012 was $78 897: 
cardiac revascularization cost $149 480, and percutaneous 
interventions cost ≈$70 027 .
●● For 2011, the estimated annual costs for CVD and stroke 
were $320 .1 billion, including $195 .6 billion in direct 
costs (hospital services, physicians and other profession-
als, prescribed medications, home health care, and other 
medical durables) and $124 .5 billion in indirect costs 
from lost future productivity (cardiovascular and stroke 
premature deaths) . CVD costs more than any other diag-
nostic group .
●● By comparison, in 2009, the estimated cost of all cancer 
and benign neoplasms was $216 .6 billion ($86 .6 billion in 
direct costs and $130 billion in mortality indirect costs) .
Conclusions
The AHA, through its Statistics Committee, continuously 
monitors and evaluates sources of data on heart disease and 
stroke in the United States to provide the most current infor-
mation available in the Statistical Update . This annual Statis-
tical Update is the product of a full year’s worth of effort by 
dedicated volunteer physicians and scientists, committed gov-
ernment professionals, and outstanding AHA staff members, 
without whom publication of this valuable resource would be 
impossible . Their contributions are gratefully acknowledged .
Dariush Mozaffarian, MD, DrPH, FAHA
Emelia J. Benjamin, MD, ScM, FAHA
Melanie B. Turner, MPH
On behalf of the American Heart Association Statistics  
  Committee and Stroke Statistics Subcommittee
Note: Population data used in the compilation of NHANES 
prevalence estimates are for the latest year of the NHANES 
survey being used . Extrapolations for NHANES prevalence 
estimates are based on the census resident population for 2012 
because this is the most recent year of NHANES data used in the 
Statistical Update .
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